BE2019C510I2 - - Google Patents

Download PDF

Info

Publication number: BE2019C510I2
Authority: BE; Belgium

Application number

BE2019C510C

Original Assignee

Astrazeneca Ab

Array Biopharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-13

Filing date

2019-03-13

Publication date

2022-05-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28041856&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2019C510(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2019-03-13 Application filed by Astrazeneca Ab, Array Biopharma Inc filed Critical Astrazeneca Ab

2022-05-19 Publication of BE2019C510I2 publication Critical patent/BE2019C510I2/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

BE2019C510C 2002-03-13 2019-03-13 BE2019C510I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US36400702P	2002-03-13	2002-03-13
PCT/US2003/007864 WO2003077914A1 (fr)	2002-03-13	2003-03-13	Utilisation de derives de benzimidazole alkyles n3 en tant qu'inhibiteurs de mek

Publications (1)

Publication Number	Publication Date
BE2019C510I2 true BE2019C510I2 (fr)	2022-05-19

Family

ID=28041856

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE2019C510C BE2019C510I2 (fr)	2002-03-13	2019-03-13

Country Status (35)

Country	Link
US (11)	US20030232869A1 (fr)
EP (5)	EP2275102B1 (fr)
JP (4)	JP4093966B2 (fr)
KR (3)	KR100984595B1 (fr)
CN (4)	CN100519539C (fr)
AR (3)	AR038971A1 (fr)
AT (1)	ATE449605T1 (fr)
AU (2)	AU2003218157C1 (fr)
BE (1)	BE2019C510I2 (fr)
BR (1)	BR122018007328B8 (fr)
CA (1)	CA2478374C (fr)
CL (2)	CL2012002380A1 (fr)
CY (3)	CY1109727T1 (fr)
DE (1)	DE60330227D1 (fr)
DK (4)	DK2130537T3 (fr)
DO (4)	DOP2003000613A (fr)
ES (5)	ES2335276T3 (fr)
HK (3)	HK1070823A1 (fr)
HU (2)	HUE025767T2 (fr)
IL (4)	IL163995A0 (fr)
IS (4)	IS2748B (fr)
LT (1)	LTC1482932I2 (fr)
LU (1)	LUC00100I2 (fr)
MX (1)	MXPA04008893A (fr)
NL (1)	NL300974I2 (fr)
NZ (1)	NZ535158A (fr)
PA (1)	PA8569301A1 (fr)
PL (5)	PL401637A1 (fr)
PT (4)	PT1482932E (fr)
SG (3)	SG148857A1 (fr)
SI (4)	SI3000810T1 (fr)
TW (3)	TWI338685B (fr)
UA (1)	UA77765C2 (fr)
WO (1)	WO2003077914A1 (fr)
ZA (1)	ZA200407220B (fr)

Families Citing this family (239)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL401637A1 (pl)	2002-03-13	2013-05-27	Array Biopharma Inc.	N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
US7235537B2 (en) *	2002-03-13	2007-06-26	Array Biopharma, Inc.	N3 alkylated benzimidazole derivatives as MEK inhibitors
EP1581527A4 (fr) *	2002-12-13	2006-11-22	Smithkline Beecham Corp	Mimetiques de la thrombopoietine
EP1598079B1 (fr) *	2003-02-26	2009-04-22	Kowa Co., Ltd.	Traitement de la dermatite de contact allergique
CA2532067C (fr)	2003-07-24	2010-12-21	Stephen Douglas Barrett	Benzimidazoles n-methyle-substitues
US7144907B2 (en)	2003-09-03	2006-12-05	Array Biopharma Inc.	Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) *	2003-09-03	2009-05-26	Array Biopharma Inc.	Method of treating inflammatory diseases
BRPI0414581C1 (pt) *	2003-09-22	2021-05-25	Mei Pharma Inc	composto, composição farmacêutica compreendendo o referido composto e uso do referido composto
WO2005051302A2 (fr) *	2003-11-19	2005-06-09	Array Biopharma Inc.	Inhibiteurs bicycliques de mek, et leurs procedes d'utilisation
US7732616B2 (en) *	2003-11-19	2010-06-08	Array Biopharma Inc.	Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) *	2003-11-19	2009-04-14	Array Biopharma Inc.	Heterocyclic inhibitors of MEK and methods of use thereof
WO2005051304A2 (fr)	2003-11-21	2005-06-09	Array Biopharma Inc.	Inhibiteurs de la proteine kinase akt
WO2005058341A2 (fr) *	2003-12-11	2005-06-30	Theravance, Inc.	Compositions a utiliser dans le traitement de maladies proliferatives cellulaires caracterisees par la presence d'une tyrosine kinase receptrice mutante
DK1802579T3 (da)	2004-10-20	2014-01-20	Merck Serono Sa	Derivater af 3-arylaminopyridin
ATE443063T1 (de) *	2004-12-01	2009-10-15	Merck Serono Sa	Ä1,2,4ütriazoloä4,3-aüpyridin-derivative zur behandlung hyperproliferativer erkrankungen
US7429667B2 (en)	2005-01-20	2008-09-30	Ardea Biosciences, Inc.	Phenylamino isothiazole carboxamidines as MEK inhibitors
KR20080019236A (ko)	2005-05-18	2008-03-03	어레이 바이오파마 인크.	Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
AR054623A1 (es) *	2005-06-23	2007-07-04	Astrazeneca Ab	PROCESO PARA PREPARAR DERIVADOS DE BENCIMIDAZOL Y COMPUESTOS INTERMEDIARIOS DE SíNTESIS DE LOS MISMOS.
KR101357361B1 (ko) *	2005-06-23	2014-02-03	아스트라제네카 아베	벤즈이미다졸 화합물의 ＳｎＡｒ 제조 방법
US8101799B2 (en)	2005-07-21	2012-01-24	Ardea Biosciences	Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
NZ567140A (en)	2005-10-07	2011-09-30	Exelixis Inc	Azetidines as MEK inhibitors for the treatment of proliferative diseases
AU2012261703B2 (en) *	2005-10-07	2015-08-13	Exelixis, Inc.	Azetidines as MEK inhibitors for the treatment of proliferative diseases
AU2013203939B2 (en) *	2005-10-07	2015-08-13	Exelixis, Inc.	Azetidines as MEK inhibitors for the treatment of proliferative diseases
US7968108B2 (en) *	2005-10-25	2011-06-28	Metbro Distributing L.P.	Hydrogen cyanamide pesticide formulations
US7572460B2 (en) *	2005-10-25	2009-08-11	Rodrigo Rodriguez-Kabana	Hydrogen cyanamide pesticide formulations
TWI405756B (zh) *	2005-12-21	2013-08-21	Array Biopharma Inc	新穎硫酸氫鹽
WO2007071951A1 (fr) *	2005-12-21	2007-06-28	Astrazeneca Ab	Sel de tosylate du 6-(4-bromo-2-chlorophenylamino)-7-fluoro-n-(2-hydroxyethoxy)-3-methyl-3h-benzimidazole-5-carboxamide, inhibiteur de mek pouvant etre employe dans le traitement du cancer
CA2534243A1 (fr)	2006-01-25	2007-07-25	Hydro Quebec	Particules d'oxyde metallique enrobees a faible taux de dissolution, procedes de preparation et utilisation dans les systemes electrochimiques
GB0601962D0 (en)	2006-01-31	2006-03-15	Ucb Sa	Therapeutic agents
WO2007121269A2 (fr)	2006-04-11	2007-10-25	Ardea Biosciences, Inc.	N-aryl-n'alkyle sulfamides utilisés comme inhibiteurs de mek
ATE483463T1 (de)	2006-04-18	2010-10-15	Ardea Biosciences Inc	Pyridonsulfonamide und pyridonsulfamide als mek- hemmer
ATE493418T1 (de)	2006-07-06	2011-01-15	Array Biopharma Inc	Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
SI2054418T1 (sl)	2006-07-06	2012-02-29	Array Biopharma Inc	Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji
BRPI0713555A2 (pt)	2006-07-06	2012-03-20	Array Biopharma, Inc.	ciclopenta [d] pirimidinas como inibidores de akt protéina cinase
US8063050B2 (en) *	2006-07-06	2011-11-22	Array Biopharma Inc.	Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2008016123A1 (fr) *	2006-08-03	2008-02-07	Takeda Pharmaceutical Company Limited	INHIBITEUR DE LA GSK-3β
CN101583616B (zh) *	2006-08-21	2012-05-30	健泰科生物技术公司	氮杂苯并噻吩基化合物及使用方法
BRPI0714635A2 (pt) *	2006-08-21	2013-06-18	Genentech Inc	compostos, composiÇço farmacÊutica, mÉtodo para inibir, o crescimento celular anormal ou tratar uma disfunÇço hiperproliferativa, mÉtodo para tratar uma doenÇa inflamatària e mÉtodo para tratar uma doenÇa autoimune
BRPI0714629A2 (pt) *	2006-08-21	2013-05-07	Genentech Inc	composto, composiÇço farmacÊutica, mÉtodo para inibir o crescimento celular, mÉtodo para tratar uma doenÇa inflamatària e mÉtodo para trataruma doenÇa auto-imune, lesço àsseo destrutiva, distérbios proliferativos, doenÇas infecciosas, doenÇas virais, doenÇas fibràticas ou doenÇas neurodegenerativas
US7999006B2 (en)	2006-12-14	2011-08-16	Exelixis, Inc.	Methods of using MEK inhibitors
JO2985B1 (ar)	2006-12-20	2016-09-05	Takeda Pharmaceuticals Co	مثبطات كينازmapk/erk
JP2010523634A (ja) *	2007-04-13	2010-07-15	アストラゼネカアクチボラグ	Ａｚｄ２１７１およびａｚｄ６２４４またはｍｅｋ阻害剤ｉｉを含む併用療法
US8509487B2 (en) *	2007-04-19	2013-08-13	Avago Technologies General Ip (Singapore) Pte. Ltd.	System and method for optically measuring a parameter of an object
EP2164850B1 (fr)	2007-06-12	2016-01-13	Genentech, Inc.	Azaindoles n-substitués et procédés d'utilisation
CN101918373B (zh) *	2007-07-05	2013-06-05	阵列生物制药公司	作为akt蛋白激酶抑制剂的嘧啶基环戊烷
US8846683B2 (en)	2007-07-05	2014-09-30	Array Biopharma, Inc.	Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en)	2007-07-05	2016-08-09	Array Biopharma Inc.	Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
KR20150089099A (ko)	2007-07-05	2015-08-04	어레이 바이오파마 인크.	Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
GB0714384D0 (en)	2007-07-23	2007-09-05	Ucb Pharma Sa	theraputic agents
WO2009050506A2 (fr) *	2007-10-15	2009-04-23	Astrazeneca Ab	Combinaison 059
ES2456966T3 (es)	2007-11-12	2014-04-24	Takeda Pharmaceutical Company Limited	Inhibidores de MAPK/ERK cinasa
CN101945870B (zh)	2007-12-19	2012-10-03	健泰科生物技术公司	5-苯氨基咪唑并吡啶和使用方法
CN101903387B (zh)	2007-12-19	2014-05-21	健泰科生物技术公司	8-苯氨基咪唑并吡啶和它们在制备抗癌剂和/或抗炎剂中的用途
CA2707650A1 (fr)	2007-12-20	2009-07-02	F. Hoffmann-La Roche Ag	Hydantoines substituees en tant qu'inhibiteurs de la mek kinase
CN101945875B (zh)	2007-12-21	2013-04-24	健泰科生物技术公司	氮杂吲嗪及其使用方法
JP5346345B2 (ja) *	2008-01-09	2013-11-20	アレイバイオファーマ、インコーポレイテッド	Ａｋｔタンパク質キナーゼ阻害剤としての水酸化されたピリミジルシクロペンタン類
WO2009089453A1 (fr)	2008-01-09	2009-07-16	Array Biopharma Inc.	Pyrimidyl cyclopentane hydroxylé en tant qu'inhibiteur de protéine kinase akt
WO2009093008A1 (fr)	2008-01-21	2009-07-30	Ucb Pharma S.A.	Dérivés de thiénopyridine utilisés comme inhibiteurs de mek
SA109300195B1 (ar)	2008-03-28	2013-04-20	Astrazeneca Ab	تركيبة صيدلانية جديدة مضادة للسرطان
GB0811304D0 (en)	2008-06-19	2008-07-30	Ucb Pharma Sa	Therapeutic agents
WO2009157167A1 (fr)	2008-06-23	2009-12-30	パナソニック株式会社	Appareil de station de base de communication sans fil et procédé d'attribution de signal de référence
EP2310373A1 (fr)	2008-07-01	2011-04-20	Genentech, Inc.	Hétérocycles bicycliques en tant qu'inhibiteurs de mek kinase
RU2495028C2 (ru)	2008-07-01	2013-10-10	Дженентек, Инк.	Изоиндолоны и способы их применения
PE20110665A1 (es)	2008-08-04	2011-09-23	Merck Patent Gmbh	Compuestos derivados de n-cichohexil-3-(fenilamino)-isonicotinamida como inhibidores de mek
CN101653607B (zh) *	2008-08-19	2013-02-13	鼎泓国际投资（香港）有限公司	含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途
EP2358202B1 (fr) *	2008-11-03	2016-06-15	Merck Sharp & Dohme Corp.	Benzimidazole et aza-benzimidazole carboxamides
JP5746630B2 (ja)	2008-11-10	2015-07-08	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	置換スルホンアミドフェノキシベンズアミド
JO3002B1 (ar)	2009-08-28	2016-09-05	Irm Llc	مركبات و تركيبات كمثبطات كيناز بروتين
US8242260B2 (en)	2009-08-28	2012-08-14	Novartis Ag	Compounds and compositions as protein kinase inhibitors
WO2011047795A1 (fr)	2009-10-21	2011-04-28	Bayer Schering Pharma Aktiengesellschaft	Benzosulfonamides substitués
CA2777304A1 (fr)	2009-10-21	2011-04-28	Marion Hitchcock	Benzosulfonamides substitues
EP2491014A1 (fr)	2009-10-21	2012-08-29	Bayer Pharma Aktiengesellschaft	Dérivés d'halogénophénoxybenzamide substitués
WO2011095807A1 (fr)	2010-02-07	2011-08-11	Astrazeneca Ab	Combinaisons d'inhibiteurs de mek et de hh
EP2560640A1 (fr)	2010-04-19	2013-02-27	Synta Pharmaceuticals Corp.	Thérapie anticancéreuse à l'aide d'une combinaison d'un composé inhibiteur de hsp90 et d'un inhibiteur d'egfr
WO2011131748A2 (fr)	2010-04-21	2011-10-27	Probiodrug Ag	Nouveaux inhibiteurs
CN103080107A (zh)	2010-06-25	2013-05-01	诺瓦提斯公司	作为蛋白激酶抑制剂的杂芳基化合物和组合物
CN103221043B (zh)	2010-08-05	2016-04-06	卡斯西部储备大学	用于治疗神经元连接发育障碍的erk抑制剂
HUE033209T2 (hu)	2010-10-06	2017-11-28	Glaxosmithkline Llc	PI3 kináz inhibitor hatású benzimidazol-származékok
US9045429B2 (en)	2010-10-29	2015-06-02	Bayer Intellectual Property Gmbh	Substituted phenoxypyridines
CN102020651B (zh)	2010-11-02	2012-07-18	北京赛林泰医药技术有限公司	6-芳基氨基吡啶酮甲酰胺mek抑制剂
KR20140063501A (ko)	2010-12-22	2014-05-27	페이트 세러퓨틱스, 인코포레이티드	단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
PL2655375T3 (pl)	2010-12-23	2015-05-29	Sanofi Sa	Pochodne pirymidynonu, ich wytwarzanie i ich farmaceutyczne zastosowanie
EP2694073B1 (fr)	2011-04-01	2018-08-08	Genentech, Inc.	Combinaisons de inhibiteurs d'akt et mek pour le traitement du cancer
CN107233343A (zh)	2011-04-01	2017-10-10	基因泰克公司	Akt抑制剂化合物和化疗剂的组合以及使用方法
WO2012145503A1 (fr)	2011-04-21	2012-10-26	Novartis Ag	Combinaisons pharmaceutiques
WO2012162293A1 (fr) *	2011-05-23	2012-11-29	Synta Pharmaceuticals Corp.	Polythérapie de composés inhibiteurs de hsp90 avec inhibiteurs de mek
ES2597052T3 (es)	2011-05-25	2017-01-13	Université Paris Descartes	Inhibidores de ERK para su uso en el tratamiento de atrofia muscular espinal
EP3812387A1 (fr)	2011-07-21	2021-04-28	Sumitomo Dainippon Pharma Oncology, Inc.	Inhibiteurs de protéine kinase hétérocycliques
UA117220C2 (uk) *	2011-08-01	2018-07-10	Дженентек, Інк.	Способи лікування раку з використанням антагоністів, що зв'язуються з віссю pd-1, і інгібіторів mek
US10307167B2 (en)	2012-12-14	2019-06-04	Corquest Medical, Inc.	Assembly and method for left atrial appendage occlusion
US10813630B2 (en)	2011-08-09	2020-10-27	Corquest Medical, Inc.	Closure system for atrial wall
US10314594B2 (en)	2012-12-14	2019-06-11	Corquest Medical, Inc.	Assembly and method for left atrial appendage occlusion
CN103764144B (zh) *	2011-08-31	2016-07-20	诺华股份有限公司	Pi3k抑制剂与mek抑制剂的协同组合
CA2845571A1 (fr) *	2011-09-01	2013-03-07	Novartis Ag	Utilisation d'un compose organique dans le traitement du syndrome de noonan
EP2570127A1 (fr)	2011-09-16	2013-03-20	Sanofi	Compositions et procédés pour traiter le cancer avec un inhibiteur bêta PI3KB et un inhibiteur de la voie MAPK, incluant des inhibiteurs MEK et RAF
JP2014530243A (ja)	2011-10-14	2014-11-17	アレイバイオファーマ、インコーポレイテッド	Ａｒｒｙ−３８０の多形体、選択的ｈｅｒｂ２阻害剤、およびそれらを含有する薬学的組成物
EP2773345A1 (fr)	2011-11-02	2014-09-10	Synta Pharmaceuticals Corp.	Thérapie anticancéreuse utilisant une combinaison d'inhibiteurs de hsp 90 et d'inhibiteurs de topoisomérase i
WO2013067165A1 (fr)	2011-11-02	2013-05-10	Synta Pharmaceuticals Corp.	Polythérapie d'inhibiteurs de hsp 90 avec des agents contenant du platine
EP2780010A1 (fr)	2011-11-14	2014-09-24	Synta Pharmaceuticals Corp.	Association thérapeutique d'inhibiteurs de hsp90 et d'inhibiteurs de braf
AU2012340766B2 (en)	2011-11-23	2018-05-10	Medimmune, Llc	Binding molecules specific for HER3 and uses thereof
WO2013082511A1 (fr)	2011-12-02	2013-06-06	Genentech, Inc.	Procédés pour surmonter la résistance tumorale aux antagonistes de vegf
US10023862B2 (en)	2012-01-09	2018-07-17	Arrowhead Pharmaceuticals, Inc.	Organic compositions to treat beta-catenin-related diseases
WO2013109142A1 (fr)	2012-01-16	2013-07-25	Stichting Het Nederlands Kanker Instituut	Inhibition de la voie des mapk/erk et pdk combinée dans des cas de néoplasie
CN103204822B (zh)	2012-01-17	2014-12-03	上海科州药物研发有限公司	作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途
GB201201332D0 (en)	2012-01-26	2012-03-14	Imp Innovations Ltd	Method
CN104487089B (zh) *	2012-03-20	2018-08-28	诺华股份有限公司	Mek抑制剂和igfir抑制剂的组合疗法
WO2013152425A1 (fr)	2012-04-09	2013-10-17	Switch Materials , Inc.	Matériaux de commutation, et compositions et procédés pour les fabriquer
WO2013177676A1 (fr)	2012-05-29	2013-12-05	Switch Materials Inc.	Filtre optique comprenant une couche à transmittance variable
CA2874905A1 (fr)	2012-05-31	2013-12-05	Bayer Pharma Aktiengesellschaft	Biomarqueurs pour la determination de la reponse efficace de traitements de patients atteints d'un carcinome hepatocellulaire (hcc)
AR091876A1 (es) *	2012-07-26	2015-03-04	Novartis Ag	Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
MX367970B (es)	2012-08-17	2019-09-11	Hoffmann La Roche	Tratamientos de combinación para melanoma que comprenden la administración de cobimetinib y vemurafinib.
LT2903968T (lt)	2012-10-02	2017-02-27	Gilead Sciences, Inc.	Histondemetilazių inhibitoriai
SI2909188T1 (en)	2012-10-12	2018-07-31	Exelixis, Inc.	A novel process for the manufacture of compounds for use in the treatment of cancer
EP2909181B1 (fr)	2012-10-16	2017-08-09	Tolero Pharmaceuticals, Inc.	Modulateurs de pkm2 et procédés pour les utiliser
ES2772498T3 (es) *	2012-10-19	2020-07-07	Array Biopharma Inc	Preparación de un inhibidor mek y formulación que comprende el mismo
US20140142689A1 (en)	2012-11-21	2014-05-22	Didier De Canniere	Device and method of treating heart valve malfunction
US9446043B2 (en)	2012-11-29	2016-09-20	Novartis Ag	Pharmaceutical combinations
WO2014097125A1 (fr)	2012-12-20	2014-06-26	Novartis Ag	Combinaison pharmaceutique comprenant du binimétinib
EP2752191A1 (fr)	2013-01-07	2014-07-09	Sanofi	Compositions et procédés utilisant un antagoniste de hdm2 et un inhibiteur de mek
US20140242595A1 (en)	2013-02-22	2014-08-28	Cellular Dynamics International, Inc.	Hepatocyte production via forward programming by combined genetic and chemical engineering
WO2014133071A1 (fr)	2013-02-27	2014-09-04	第一三共株式会社	Procédé de prédiction de la réactivité à un composé inhibant la voie de transduction du signal de mapk
PL2961736T3 (pl)	2013-02-27	2018-08-31	Gilead Sciences, Inc.	Inhibitory demetylaz histonowych
EP2970205B1 (fr)	2013-03-14	2019-05-08	Tolero Pharmaceuticals, Inc.	Inhibiteurs de jak2 et alk2 et leurs procédés d'utilisation
MA38522A1 (fr) *	2013-03-21	2017-10-31	Novartis Ag	Thérapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur.
AR097617A1 (es)	2013-09-13	2016-04-06	Actelion Pharmaceuticals Ltd	Derivados antibacterianos del 2h-indazol
WO2015041534A1 (fr)	2013-09-20	2015-03-26	Stichting Het Nederlands Kanker Instituut	P90rsk en combinaison avec raf/erk/mek
WO2015041533A1 (fr)	2013-09-20	2015-03-26	Stichting Het Nederlands Kanker Instituut	Association de rock et de la voie mapk
US10570204B2 (en)	2013-09-26	2020-02-25	The Medical College Of Wisconsin, Inc.	Methods for treating hematologic cancers
US9566443B2 (en)	2013-11-26	2017-02-14	Corquest Medical, Inc.	System for treating heart valve malfunction including mitral regurgitation
MA39189A1 (fr)	2013-12-19	2017-06-30	Actelion Pharmaceuticals Ltd	Dérivés de 1h-indazole et de 1h-indole antibactériens
CN104788365B (zh) *	2014-01-16	2018-08-10	上海艾力斯医药科技有限公司	异烟酰胺衍生物、其制备方法及应用
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
AU2015227184B2 (en)	2014-03-04	2021-05-20	Fate Therapeutics, Inc.	Improved reprogramming methods and cell culture platforms
AR099612A1 (es)	2014-03-04	2016-08-03	Actelion Pharmaceuticals Ltd	Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
TWI697500B (zh)	2014-03-14	2020-07-01	瑞士商諾華公司	針對ｌａｇ-３之抗體分子及其用途
EP3126345A1 (fr)	2014-03-31	2017-02-08	Gilead Sciences, Inc.	Inhibiteurs d'histones déméthylases
US20170107486A1 (en)	2014-04-21	2017-04-20	Cellular Dynamics International, Inc.	Hepatocyte production via forward programming by combined genetic and chemical engineering
ES2687040T3 (es)	2014-05-16	2018-10-23	Idorsia Pharmaceuticals Ltd	Derivados antibacterianos de quinazolin4(3H)ona
US10023879B2 (en)	2014-06-04	2018-07-17	Fate Therapeutics, Inc.	Minimal volume reprogramming of mononuclear cells
JP6673896B2 (ja)	2014-07-15	2020-03-25	ジェネンテック，インコーポレイテッド	Ｐｄ−１軸結合アンタゴニスト及びｍｅｋ阻害剤を使用した癌を処置するための組成物
AR101692A1 (es)	2014-08-27	2017-01-04	Epitherapeutics Aps	Compuestos y métodos para inhibir histonas demetilasas
CA2960824A1 (fr)	2014-09-13	2016-03-17	Novartis Ag	Therapies combinees d'inhibiteurs d'alk
ES2774448T3 (es)	2014-10-03	2020-07-21	Novartis Ag	Terapias de combinación
WO2016057367A1 (fr)	2014-10-06	2016-04-14	Dana-Farber Cancer Institute, Inc.	Biomarqueurs à base d'angiopoïétine -2 utilisés pour la prédiction de la réponse de point de contrôle anti-immunitaire
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN114920840A (zh)	2014-10-14	2022-08-19	诺华股份有限公司	针对pd-l1的抗体分子及其用途
US10842626B2 (en)	2014-12-09	2020-11-24	Didier De Canniere	Intracardiac device to correct mitral regurgitation
US20170340733A1 (en)	2014-12-19	2017-11-30	Novartis Ag	Combination therapies
HUE043060T2 (hu)	2014-12-23	2019-07-29	Novartis Ag	Triazolopirimidin-vegyületek és alkalmazásaik
SG10202101358XA (en)	2015-01-26	2021-03-30	Fate Therapeutics Inc	Methods and compositions for inducing hematopoietic cell differentiation
CN105566225A (zh) *	2015-02-16	2016-05-11	苏州晶云药物科技有限公司	一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
JP2016155776A (ja) *	2015-02-24	2016-09-01	学校法人兵庫医科大学	抗腫瘍効果増強剤および抗腫瘍剤
TN2017000375A1 (en)	2015-03-10	2019-01-16	Aduro Biotech Inc	Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
CN107667092B (zh)	2015-03-25	2021-05-28	诺华股份有限公司	作为fgfr4抑制剂的甲酰化n-杂环衍生物
MA41866A (fr)	2015-03-31	2018-02-06	Massachusetts Gen Hospital	Molécules à auto-assemblage pour l'administration ciblée de médicaments
EP3316902A1 (fr)	2015-07-29	2018-05-09	Novartis AG	Polythérapies comprenant des molécules d'anticorps contre tim -3
EP3317301B1 (fr)	2015-07-29	2021-04-07	Novartis AG	Polythérapies comprenant des molécules d'anticorps dirigées contre lag-3
AR105646A1 (es)	2015-08-11	2017-10-25	Actelion Pharmaceuticals Ltd	Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
WO2017033113A1 (fr)	2015-08-21	2017-03-02	Acerta Pharma B.V.	Associations thérapeutiques d'un inhibiteur de mek et d'un inhibiteur de btk
CN111821306A (zh)	2015-08-28	2020-10-27	诺华股份有限公司	Mdm2抑制剂和其组合
AR105889A1 (es)	2015-09-03	2017-11-22	Actelion Pharmaceuticals Ltd	Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
CN117737124A (zh)	2015-10-16	2024-03-22	菲特治疗公司	用于诱导和维护基态多能性的平台
MX2018005550A (es)	2015-11-03	2019-07-18	Janssen Biotech Inc	Anticuerpos que se unen especificamente a tim-3 y sus usos.
CN115806940A (zh)	2015-11-04	2023-03-17	菲特治疗公司	多能细胞的基因组工程改造
WO2017078807A1 (fr)	2015-11-04	2017-05-11	Fate Therapeutics, Inc.	Procédés et compositions pour induire la différenciation de cellules hématopoïétiques
JP2019503349A (ja)	2015-12-17	2019-02-07	ノバルティスアーゲー	Ｐｄ−１に対する抗体分子およびその使用
US11413309B2 (en)	2016-01-20	2022-08-16	Fate Therapeutics, Inc.	Compositions and methods for immune cell modulation in adoptive immunotherapies
AU2017210031C1 (en)	2016-01-20	2020-11-26	Fate Therapeutics, Inc.	Compositions and methods for immune cell modulation in adoptive immunotherapies
US11883404B2 (en)	2016-03-04	2024-01-30	Taiho Pharmaceuticals Co., Ltd.	Preparation and composition for treatment of malignant tumors
AR108257A1 (es)	2016-05-02	2018-08-01	Mei Pharma Inc	Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
CN109890386B (zh)	2016-06-03	2022-05-24	阵列生物制药公司	药物组合
EP3472168B1 (fr)	2016-06-20	2024-01-10	Novartis AG	Formes cristallines d'un composé de triazolopyrimidine
WO2017221092A1 (fr)	2016-06-20	2017-12-28	Novartis Ag	Composés de triazolopyridine et leurs utilisations
CN109790166A (zh)	2016-06-20	2019-05-21	诺华股份有限公司	咪唑并吡啶化合物用于治疗癌症
WO2018009466A1 (fr)	2016-07-05	2018-01-11	Aduro Biotech, Inc.	Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations
WO2018065924A1 (fr) *	2016-10-04	2018-04-12	Sun Pharmaceutical Industries Limited	Intermédiaires d'inhibiteurs de la protéine kinase kinase activée par mitogène (map2k ou mek) et leur procédé de préparation
WO2018092064A1 (fr)	2016-11-18	2018-05-24	Novartis Ag	Combinaisons d'inhibiteurs de mdm2 et d'inhibiteurs de bcl-xl
CN108084078B (zh) *	2016-11-24	2021-07-30	中山大学	一种治疗银屑病性关节炎疾病的药物阿普斯特的合成方法
WO2018106595A1 (fr)	2016-12-05	2018-06-14	Fate Therapeutics, Inc.	Compositions et procédés pour la modulation de cellules immunitaires dans des immunothérapies adoptives
EP3372624A1 (fr)	2017-03-06	2018-09-12	Henkel AG & Co. KGaA	Composition à un composant à base de composés ayant au moins deux unités de carbonate cyclique exo-vinylène
UY37695A (es)	2017-04-28	2018-11-30	Novartis Ag	Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN109438362B (zh) *	2017-11-14	2020-07-21	深圳市塔吉瑞生物医药有限公司	一种取代的苯并咪唑化合物及包含该化合物的组合物
JP2021503478A (ja)	2017-11-16	2021-02-12	ノバルティスアーゲー	組み合わせ治療
TW201938165A (zh)	2017-12-18	2019-10-01	美商輝瑞股份有限公司	治療癌症的方法及組合療法
MX2020009762A (es)	2018-03-19	2021-01-08	Taiho Pharmaceutical Co Ltd	Composicion farmaceutica que incluye alquil sulfato de sodio.
BR112020020246A8 (pt)	2018-04-05	2022-10-18	Sumitomo Dainippon Pharma Oncology Inc	Inibidores de cinase axl e uso dos mesmos
MX2020012598A (es)	2018-05-24	2021-05-27	Janssen Biotech Inc	Agentes aglutinantes del psma y usos de estos.
AR116109A1 (es)	2018-07-10	2021-03-31	Novartis Ag	Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020021465A1 (fr)	2018-07-25	2020-01-30	Advanced Accelerator Applications (Italy) S.R.L.	Procédé de traitement de tumeurs neuroendocrines
KR102643582B1 (ko)	2018-07-25	2024-03-05	어드밴스드 엑셀러레이터 어플리케이션즈	안정한 농축 방사성 핵종 복합체 용액
CN112512597A (zh)	2018-07-26	2021-03-16	大日本住友制药肿瘤公司	用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂
JP7328323B2 (ja)	2018-08-17	2023-08-16	ノバルティスアーゲー	ＳＭＡＲＣＡ２／ＢＲＭＡＴＰａｓｅ阻害剤としての尿素化合物及び組成物
WO2020064693A1 (fr)	2018-09-25	2020-04-02	Advanced Accelerator Applications (Italy) Srl	Polythérapie
CN113473978A (zh)	2018-11-20	2021-10-01	恩福莱克逊治疗有限公司	用于治疗皮肤疾病氰基芳烃-苯胺化合物
JP2022514315A (ja)	2018-12-20	2022-02-10	ノバルティスアーゲー	３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体を含む投与計画及び薬剤組み合わせ
TW202038957A (zh)	2018-12-21	2020-11-01	日商第一三共股份有限公司	抗體-藥物結合物與激酶抑制劑之組合
CA3127502A1 (fr)	2019-02-12	2020-08-20	Sumitomo Dainippon Pharma Oncology, Inc.	Formulations comprenant des inhibiteurs de proteine kinase heterocycliques
CN113329792A (zh)	2019-02-15	2021-08-31	诺华股份有限公司	取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
WO2020165833A1 (fr)	2019-02-15	2020-08-20	Novartis Ag	Dérivés de 3-(1-oxo-5-(pipéridin-4-yl)isoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations
JP2022526713A (ja)	2019-03-21	2022-05-26	オンクセオ	がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
KR20210141621A (ko)	2019-03-22	2021-11-23	스미토모 다이니폰 파마 온콜로지, 인크.	Pkm2 조정제를 포함하는 조성물 및 그를 사용한 치료 방법
WO2020212832A1 (fr) *	2019-04-16	2020-10-22	Alembic Pharmaceuticals Limited	Procédé de préparation de composés de benzimidazole
MA55717A (fr)	2019-04-19	2022-02-23	Janssen Biotech Inc	Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3
TWI817018B (zh)	2019-06-28	2023-10-01	美商艾瑞生藥股份有限公司	用於治療ｂｒａｆ相關的疾病和失調症之化合物
JP2022539208A (ja)	2019-07-03	2022-09-07	スミトモファーマオンコロジー，インコーポレイテッド	チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
CN114761006A (zh)	2019-11-08	2022-07-15	Inserm(法国国家健康医学研究院)	对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021116901A1 (fr) *	2019-12-09	2021-06-17	Biocon Limited	Formes de binimétinib et procédé de préparation correspondant
EP4077389A1 (fr)	2019-12-20	2022-10-26	Novartis AG	Combinaison d'anticorps anti-tim-3 mbg453 et d'anticorps anti-tgf-bêta nis793, avec ou sans décitabine ou l'anticorps anti pd-1 spartalizumab, pour le traitement de la myélofibrose et du syndrome myélodysplasique
WO2021148581A1 (fr)	2020-01-22	2021-07-29	Onxeo	Nouvelle molécule dbait et son utilisation
WO2021185291A1 (fr) *	2020-03-17	2021-09-23	南京明德新药研发有限公司	Régulateur de protéolyse et son procédé d'utilisation
EP4134081A1 (fr)	2020-04-10	2023-02-15	Taiho Pharmaceutical Co., Ltd.	Thérapie contre le cancer à l'aide d'un composé d'alcynyle benzène 3,5-disubstitué et un inhibiteur de mek
IL298300A (en)	2020-06-09	2023-01-01	Array Biopharma Inc	4-oxo-3,4-dihydroquinazolinone compounds for the treatment of braf-related diseases and disorders
KR20230027056A (ko)	2020-06-23	2023-02-27	노파르티스 아게	3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
AR123185A1 (es)	2020-08-10	2022-11-09	Novartis Ag	Compuestos y composiciones para inhibir ezh2
US20230321285A1 (en)	2020-08-31	2023-10-12	Advanced Accelerator Applications International Sa	Method of treating psma-expressing cancers
WO2022043556A1 (fr)	2020-08-31	2022-03-03	Novartis Ag	Composition pharmaceutique stable
EP4204020A1 (fr)	2020-08-31	2023-07-05	Advanced Accelerator Applications International S.A.	Méthode de traitement de cancers exprimant le psma
MX2023003867A (es)	2020-10-05	2023-04-18	Pf Medicament	Combinacion de encorafenib y binimetinib a manera de tratamiento adyuvante contra melanoma resecado en etapa ii.
TW202237119A (zh)	2020-12-10	2022-10-01	美商住友製藥腫瘤公司	Ａｌｋ﹘５抑制劑和彼之用途
CN112679438A (zh) *	2020-12-31	2021-04-20	武汉九州钰民医药科技有限公司	制备司美替尼的方法
CN112759552A (zh) *	2020-12-31	2021-05-07	武汉九州钰民医药科技有限公司	司美替尼的合成方法
CN117136056A (zh) *	2021-01-21	2023-11-28	恩福莱克逊治疗有限公司	吡咯并吡啶-苯胺化合物的制备方法
AU2022214491A1 (en)	2021-01-28	2023-09-14	Janssen Biotech, Inc.	Psma binding proteins and uses thereof
CN117794929A (zh)	2021-02-02	2024-03-29	法国施维雅药厂	选择性bcl-xl protac化合物及使用方法
WO2022195551A1 (fr)	2021-03-18	2022-09-22	Novartis Ag	Biomarqueurs pour le cancer et leurs méthodes d'utilisation
TW202304979A (zh)	2021-04-07	2023-02-01	瑞士商諾華公司	抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
KR20230170039A (ko)	2021-04-13	2023-12-18	뉴베일런트, 아이엔씨.	Egfr 돌연변이를 지니는 암을 치료하기 위한 아미노-치환된 헤테로사이클
EP4322953A1 (fr) *	2021-04-15	2024-02-21	Ideaya Biosciences, Inc.	Polythérapie comprenant un inhibiteur de pkc et un inhibiteur de mek
AR125874A1 (es)	2021-05-18	2023-08-23	Novartis Ag	Terapias de combinación
TW202313046A (zh)	2021-06-09	2023-04-01	瑞士商赫孚孟拉羅股份公司	用於癌症治療之組合療法
WO2022262699A1 (fr) *	2021-06-17	2022-12-22	深圳市塔吉瑞生物医药有限公司	Composé de benzimidazole substitué, composition le contenant et utilisation associée
AU2022306297A1 (en)	2021-07-09	2024-02-08	Plexium, Inc.	Aryl compounds and pharmaceutical compositions that modulate ikzf2
CA3230652A1 (fr)	2021-11-04	2023-05-11	F. Hoffmann-La Roche Ag	Nouvelle utilisation d'un compose quinazolinone pour le traitement du cancer
WO2023084489A1 (fr)	2021-11-15	2023-05-19	Pfizer Inc.	Procédés de traitement de la maladie à coronavirus 2019
TW202342018A (zh)	2022-03-04	2023-11-01	美商奇奈特生物製藥公司	Mek激酶抑制劑
WO2023225336A1 (fr)	2022-05-20	2023-11-23	Novartis Ag	Conjugués anticorps-médicament inhibiteurs de met bcl-xl et leurs procédés d'utilisation
WO2023225320A1 (fr)	2022-05-20	2023-11-23	Novartis Ag	Conjugués anticorps-médicament inhibiteurs de bcl-xl et méthodes d'utilisation associées
WO2023238000A1 (fr) *	2022-06-06	2023-12-14	Glenmark Life Sciences Limited	Procédé de préparation de sélumétinib et de sels de celui-ci

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1980001113A1 (fr)	1978-11-20	1980-05-29	Braun Ag	Garde-temps, en particulier horloge pilotee a quartz
GB8607683D0 (en)	1986-03-27	1986-04-30	Ici Plc	Anti-tumor agents
GB8827305D0 (en)	1988-11-23	1988-12-29	British Bio Technology	Compounds
US5250554A (en) *	1989-10-24	1993-10-05	Takeda Chemical Industries, Ltd.	Benzimidazole derivatives useful as angiotensin II inhibitors
IL95975A (en)	1989-10-24	1997-06-10	Takeda Chemical Industries Ltd	N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
US5218356A (en) *	1991-05-31	1993-06-08	Guenther Knapp	Wireless indoor data relay system
US5216003A (en) *	1992-01-02	1993-06-01	G. D. Searle & Co.	Diacid-containing benzimidazole compounds for treatment of neurotoxic injury
US5455258A (en)	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
EP0710654A4 (fr)	1993-07-23	1996-08-28	Green Cross Corp	Derive de triazole et son utilisation pharmaceutique
EP0639573A1 (fr)	1993-08-03	1995-02-22	Hoechst Aktiengesellschaft	Hétérocycles à cinq chaînons benzocondensés, procédé pour leur préparation, leur utilisation comme médicament et comme diagnostique aussi bien que les produits pharmaceutiques le contenant
NZ270985A (en)	1994-04-29	1997-06-24	Lilly Co Eli	Substituted benzimidazole derivatives; medicaments and preparation of medicaments
US5520187A (en) *	1994-11-25	1996-05-28	General Electric Company	Ultrasonic probe with programmable multiplexer for imaging systems with different channel counts
US5525625A (en)	1995-01-24	1996-06-11	Warner-Lambert Company	2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US5863949A (en)	1995-03-08	1999-01-26	Pfizer Inc	Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (fr)	1995-04-20	2001-07-24	Pfizer Inc.	Derives d'acide hydroxamique arylsufonyle en tant qu'inhibiteurs de mmp et de tnf
US5972980A (en) *	1995-10-05	1999-10-26	Warner-Lambert Company	Method for treating and preventing inflammation and atherosclerosis
DK0780386T3 (da)	1995-12-20	2003-02-03	Hoffmann La Roche	Matrixmetalloproteaseinhibitorer
GB9600344D0 (en) *	1996-01-09	1996-03-13	Lilly Co Eli	Benzimidzolyl neuropeptide y receptor antagonists
TR199900066T2 (xx)	1996-07-18	1999-04-21	Pfizer Inc.	Matriks metalloproteazlar�n fosfinat bazl� inhibit�rleri
IL128189A0 (en)	1996-08-23	1999-11-30	Pfizer	Arylsulfonylamino hydroxamic acid derivatives
US6077864A (en)	1997-01-06	2000-06-20	Pfizer Inc.	Cyclic sulfone derivatives
PL335027A1 (en)	1997-02-03	2000-03-27	Pfizer Prod Inc	Derivatives of arylsulphonylamino hydroxamic acid
CA2279863A1 (fr)	1997-02-07	1998-08-13	Pfizer Inc.	Derives du n-hxdroxy-beta-sulfonyl-propionamide et leur utilisation comme inhibiteurs des metalloproteases matrices
BR9807678A (pt)	1997-02-11	2000-02-15	Pfizer	Derivados de ácidos arilsulfonil-hidroxâmicos
UA73073C2 (uk)	1997-04-03	2005-06-15	Уайт Холдінгз Корпорейшн	Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6506798B1 (en) *	1997-07-01	2003-01-14	Warner-Lambert Company	4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
US6310060B1 (en)	1998-06-24	2001-10-30	Warner-Lambert Company	2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
NZ501277A (en)	1997-07-01	2002-12-20	Warner Lambert Co	-2(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6821963B2 (en) *	1997-07-01	2004-11-23	Warner-Lambert Company	4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
PT993439E (pt)	1997-07-01	2004-12-31	Warner Lambert Co	Derivados de acido 4-bromo ou 4-iodofenilaminobenzidroxamico e sua utilizacao como inibidores de mek
GB9725782D0 (en)	1997-12-05	1998-02-04	Pfizer Ltd	Therapeutic agents
GB9801690D0 (en)	1998-01-27	1998-03-25	Pfizer Ltd	Therapeutic agents
PA8469501A1 (es)	1998-04-10	2000-09-29	Pfizer Prod Inc	Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es)	1998-04-10	2000-05-24	Pfizer Prod Inc	Derivados biciclicos del acido hidroxamico
US6534503B1 (en) *	1998-04-28	2003-03-18	Lion Bioscience Ag	Melanocortin receptor-3 ligands to treat sexual dysfunction
AUPP616498A0 (en)	1998-09-25	1998-10-15	University Of Queensland, The	Synthesis of cyclic peptides
US6696440B1 (en)	1999-01-07	2004-02-24	Warner-Lambert Company	Treatment of asthma with MEK inhibitors
WO2000040237A1 (fr)	1999-01-07	2000-07-13	Warner-Lambert Company	Methode antivirale utilisant des inhibiteurs de mek
EP1144385B1 (fr) *	1999-01-13	2005-08-17	Warner-Lambert Company Llc	Les benzoheterocycles et leur utilisation comme inhibiteurs de mek
JP2000204077A (ja)	1999-01-13	2000-07-25	Warner Lambert Co	ジアリ―ルアミン
OA11819A (en)	1999-01-13	2005-08-17	Warner Lambert Co	1-Heterocycle substituted diarylamines.
EP1144371B1 (fr)	1999-01-13	2005-11-09	Warner-Lambert Company Llc	Derives de benzenesulfonamide et leur utilisation comme inhibiteurs de mek
EP1150950A2 (fr)	1999-01-13	2001-11-07	Warner-Lambert Company	Derives d'acide anthranilique
CA2349467A1 (fr)	1999-01-13	2000-07-20	Warner-Lambert Company	Acides sulfo-hydroxamiques et sulfo-hydroxamates et leur utilisation comme inhibiteurs mk
CA2348236A1 (fr)	1999-01-13	2000-07-20	Stephen Douglas Barrett	4-arylamino, 4-aryloxy, et 4-arylthio diarylamines et leurs derives comme inhibiteurs selectifs de mek
GB9910577D0 (en)	1999-05-08	1999-07-07	Zeneca Ltd	Chemical compounds
GB9912961D0 (en)	1999-06-03	1999-08-04	Pfizer Ltd	Metalloprotease inhibitors
CA2378381A1 (fr)	1999-07-16	2001-01-25	Warner-Lambert Company	Traitement de douleurs chroniques au moyen d'inhibiteurs de mek
HUP0202381A3 (en)	1999-07-16	2004-12-28	Warner Lambert Co	Method for treating chronic pain using mek inhibitors
CA2377092A1 (fr) *	1999-07-16	2001-01-25	Warner-Lambert Company	Methode de traitement de la douleur chronique au moyen d'inhibiteurs de mek
NZ515567A (en)	1999-07-16	2004-03-26	Warner Lambert Co	Method for treating chronic pain using MEK inhibitors
US7030119B1 (en) *	1999-07-16	2006-04-18	Warner-Lambert Company	Method for treating chronic pain using MEK inhibitors
WO2001021634A1 (fr)	1999-09-21	2001-03-29	Lion Bioscience Ag	Derives de benzimidazole et bibliotheques combinatoires contenant ces derives
EP1339702A1 (fr)	2000-03-15	2003-09-03	Warner-Lambert Company	Diarylamines a substitution 5-amide, utilises en tant qu'inhibiteur de kinases erk mitogenes mek
CA2403017A1 (fr)	2000-03-15	2001-09-20	Warner-Lambert Company	Diarylamines a substitution 5-amide, utilises en tant qu'inhibiteur de kinases erk mitogenes mek
EE05450B1 (et)	2000-07-19	2011-08-15	Warner-Lambert Company	4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine
AP2001002249A0 (en)	2000-08-25	2001-09-30	Warner Lambert Co	Process for making N-ARYL-ANTHRANILIC acids and their derivatives.
EP1337524A1 (fr)	2000-11-02	2003-08-27	AstraZeneca AB	Quinolines substituees comme agents antitumoraux
AU2002221239A1 (en) *	2000-12-07	2002-06-18	Astrazeneca Ab	Therapeutic benzimidazole compounds
US7102009B2 (en) *	2001-01-12	2006-09-05	Amgen Inc.	Substituted amine derivatives and methods of use
AU2002336273A1 (en) *	2001-03-09	2002-09-24	Ortho-Mcneil Pharmaceutical, Inc.	Heterocyclic compounds and their use as histamine h4 ligands.
US20040039208A1 (en)	2001-07-20	2004-02-26	Chen Michael Huai Gu	Process for making n-aryl-anthranilic acids and their derivatives
WO2003024899A2 (fr) *	2001-09-17	2003-03-27	Bristol-Myers Squibb Company	Acides hydroxamiques cycliques utilises comme inhibiteurs de metalloproteinases matricielles et/ou d'enzyme de conversion du tnf-$g(a) (tace)
WO2003054180A1 (fr)	2001-12-21	2003-07-03	Warner-Lambert Company Llc	Peptides mek1 et mek2 modifies, cristal d'un complexe peptide/ligand/cofacteur contenant de tels peptides mek1 ou mek2 modifies et leurs procedes d'utilisation
BR0307060A (pt)	2002-01-23	2004-10-26	Warner Lambert Co	ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
US7235537B2 (en) *	2002-03-13	2007-06-26	Array Biopharma, Inc.	N3 alkylated benzimidazole derivatives as MEK inhibitors
PL401637A1 (pl)	2002-03-13	2013-05-27	Array Biopharma Inc.	N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
MXPA04008894A (es) *	2002-03-13	2005-06-20	Array Biopharma Inc	Derivados de bencimidazol n3 alquilados como inhibidores de mek.
DE10238002A1 (de) *	2002-08-20	2004-03-04	Merck Patent Gmbh	Benzimidazolderivate
US20040127395A1 (en) *	2002-09-06	2004-07-01	Desai Pragnya J.	Use of histamine H4 receptor modulators for the treatment of allergy and asthma
CN1694704A (zh) *	2002-09-06	2005-11-09	詹森药业有限公司	（1h－苯并咪唑－2－基）－（哌嗪基）－甲酮衍生物及其相关化合物作为组胺h4受体拮抗剂用于治疗炎性和过敏性疾病
US7582635B2 (en) *	2002-12-24	2009-09-01	Purdue Pharma, L.P.	Therapeutic agents useful for treating pain
CA2532067C (fr)	2003-07-24	2010-12-21	Stephen Douglas Barrett	Benzimidazoles n-methyle-substitues
DE102005032379A1 (de)	2005-07-08	2007-01-11	Conti Temic Microelectronic Gmbh	Zugangskontrollsystem für ein Kraftfahrzeug
TWI405756B (zh)	2005-12-21	2013-08-21	Array Biopharma Inc	新穎硫酸氫鹽
WO2014097125A1 (fr)	2012-12-20	2014-06-26	Novartis Ag	Combinaison pharmaceutique comprenant du binimétinib

2003
- 2003-03-13 PL PL401637A patent/PL401637A1/pl unknown
- 2003-03-13 UA UA20040907722A patent/UA77765C2/uk unknown
- 2003-03-13 DE DE60330227T patent/DE60330227D1/de not_active Expired - Lifetime
- 2003-03-13 KR KR1020047014182A patent/KR100984595B1/ko active IP Right Grant
- 2003-03-13 IL IL16399503A patent/IL163995A0/xx unknown
- 2003-03-13 NZ NZ535158A patent/NZ535158A/en not_active IP Right Cessation
- 2003-03-13 AU AU2003218157A patent/AU2003218157C1/en active Active
- 2003-03-13 AR ARP030100887A patent/AR038971A1/es active IP Right Grant
- 2003-03-13 EP EP10011691.2A patent/EP2275102B1/fr not_active Expired - Lifetime
- 2003-03-13 SI SI200332546T patent/SI3000810T1/sl unknown
- 2003-03-13 DO DO2003000613A patent/DOP2003000613A/es unknown
- 2003-03-13 SI SI200332449T patent/SI2275102T1/sl unknown
- 2003-03-13 ZA ZA200407220A patent/ZA200407220B/xx unknown
- 2003-03-13 PA PA20038569301A patent/PA8569301A1/es unknown
- 2003-03-13 KR KR1020107007539A patent/KR100984573B1/ko active IP Right Grant
- 2003-03-13 JP JP2003575967A patent/JP4093966B2/ja not_active Expired - Lifetime
- 2003-03-13 TW TW092105718A patent/TWI338685B/zh not_active IP Right Cessation
- 2003-03-13 SG SG200608672-2A patent/SG148857A1/en unknown
- 2003-03-13 CN CNB038107546A patent/CN100519539C/zh not_active Expired - Lifetime
- 2003-03-13 PL PL401638A patent/PL401638A1/pl unknown
- 2003-03-13 CN CN2008101903429A patent/CN101486682B/zh not_active Expired - Lifetime
- 2003-03-13 SG SG2011042850A patent/SG194238A1/en unknown
- 2003-03-13 PL PL401635A patent/PL233177B1/pl unknown
- 2003-03-13 WO PCT/US2003/007864 patent/WO2003077914A1/fr active Application Filing
- 2003-03-13 DK DK09011389.5T patent/DK2130537T3/da active
- 2003-03-13 EP EP15177189.6A patent/EP3000810B1/fr not_active Revoked
- 2003-03-13 PT PT03714148T patent/PT1482932E/pt unknown
- 2003-03-13 ES ES03714148T patent/ES2335276T3/es not_active Expired - Lifetime
- 2003-03-13 EP EP09011389A patent/EP2130537B1/fr not_active Expired - Lifetime
- 2003-03-13 EP EP09011388.7A patent/EP2130536B1/fr not_active Expired - Lifetime
- 2003-03-13 CN CN2009101492905A patent/CN101633644B/zh not_active Expired - Lifetime
- 2003-03-13 SI SI200332221T patent/SI2130537T1/sl unknown
- 2003-03-13 CA CA002478374A patent/CA2478374C/fr not_active Expired - Lifetime
- 2003-03-13 PT PT90113895T patent/PT2130537E/pt unknown
- 2003-03-13 US US10/387,879 patent/US20030232869A1/en not_active Abandoned
- 2003-03-13 PT PT100116912T patent/PT2275102E/pt unknown
- 2003-03-13 DK DK03714148.8T patent/DK1482932T3/da active
- 2003-03-13 KR KR1020107007537A patent/KR100984613B1/ko active Protection Beyond IP Right Term
- 2003-03-13 ES ES10011691.2T patent/ES2549159T3/es not_active Expired - Lifetime
- 2003-03-13 DK DK15177189.6T patent/DK3000810T3/en active
- 2003-03-13 ES ES09011389T patent/ES2394347T3/es not_active Expired - Lifetime
- 2003-03-13 TW TW099113379A patent/TWI343377B/zh not_active IP Right Cessation
- 2003-03-13 SG SG2013013339A patent/SG2013013339A/en unknown
- 2003-03-13 PL PL401636A patent/PL233493B1/pl unknown
- 2003-03-13 SI SI200331731T patent/SI1482932T1/sl unknown
- 2003-03-13 PT PT151771896T patent/PT3000810T/pt unknown
- 2003-03-13 MX MXPA04008893A patent/MXPA04008893A/es active IP Right Grant
- 2003-03-13 DK DK10011691.2T patent/DK2275102T3/en active
- 2003-03-13 EP EP03714148A patent/EP1482932B1/fr not_active Expired - Lifetime
- 2003-03-13 HU HUE10011691A patent/HUE025767T2/en unknown
- 2003-03-13 TW TW099113360A patent/TWI350285B/zh not_active IP Right Cessation
- 2003-03-13 ES ES15177189.6T patent/ES2635666T3/es not_active Expired - Lifetime
- 2003-03-13 AT AT03714148T patent/ATE449605T1/de active
- 2003-03-13 CN CN200910149291XA patent/CN101633645B/zh not_active Expired - Lifetime
- 2003-03-13 PL PL377628A patent/PL230179B1/pl unknown
- 2003-03-13 ES ES09011388T patent/ES2407849T3/es not_active Expired - Lifetime
- 2003-12-12 BR BR122018007328A patent/BR122018007328B8/pt active IP Right Grant
2004
- 2004-09-09 IL IL163995A patent/IL163995A/en active IP Right Grant
- 2004-09-09 IS IS7442A patent/IS2748B/is unknown
2005
- 2005-02-18 US US11/061,336 patent/US7425637B2/en not_active Expired - Lifetime
- 2005-04-26 HK HK05103569.0A patent/HK1070823A1/xx not_active IP Right Cessation
2007
- 2007-10-09 JP JP2007263512A patent/JP2008019277A/ja active Pending
2008
- 2008-01-29 JP JP2008017547A patent/JP5102642B2/ja not_active Expired - Lifetime
- 2008-03-18 US US12/050,827 patent/US7777050B2/en not_active Expired - Lifetime
- 2008-03-18 US US12/050,847 patent/US7576114B2/en not_active Expired - Lifetime
2009
- 2009-10-07 AU AU2009222613A patent/AU2009222613B2/en active Active
2010
- 2010-01-13 CY CY20101100037T patent/CY1109727T1/el unknown
- 2010-03-10 IL IL204419A patent/IL204419A/en active IP Right Grant
- 2010-03-10 IL IL204420A patent/IL204420A/en active Protection Beyond IP Right Term
- 2010-06-09 HK HK10105717.9A patent/HK1141976A1/xx not_active IP Right Cessation
- 2010-06-28 US US12/824,477 patent/US8003805B2/en not_active Expired - Lifetime
- 2010-06-28 US US12/824,547 patent/US8193230B2/en not_active Expired - Lifetime
- 2010-06-28 US US12/824,559 patent/US8178693B2/en not_active Expired - Lifetime
- 2010-06-28 US US12/824,521 patent/US8193229B2/en not_active Expired - Lifetime
- 2010-06-28 US US12/824,497 patent/US7973170B2/en not_active Expired - Lifetime
- 2010-06-29 US US12/826,158 patent/US8193231B2/en not_active Expired - Lifetime
2011
- 2011-04-20 DO DO2011000110A patent/DOP2011000110A/es unknown
- 2011-04-20 DO DO2011000109A patent/DOP2011000109A/es unknown
- 2011-06-16 IS IS8959A patent/IS2990B/is unknown
- 2011-06-16 IS IS8960A patent/IS2998B/is unknown
- 2011-06-16 IS IS8961A patent/IS2999B/is unknown
- 2011-07-13 HK HK11107302.5A patent/HK1153139A1/zh not_active IP Right Cessation
2012
- 2012-05-03 US US13/463,487 patent/US8513293B2/en not_active Expired - Lifetime
- 2012-08-24 JP JP2012184708A patent/JP5498546B2/ja not_active Expired - Lifetime
- 2012-08-29 CL CL2012002380A patent/CL2012002380A1/es unknown
- 2012-08-29 CL CL2012002381A patent/CL2012002381A1/es unknown
2013
- 2013-01-28 DO DO2013000023A patent/DOP2013000023A/es unknown
- 2013-02-25 AR ARP130100567A patent/AR090143A2/es unknown
- 2013-02-25 AR ARP130100568A patent/AR090144A2/es unknown
2017
- 2017-07-27 CY CY20171100805T patent/CY1119136T1/el unknown
2019
- 2019-02-12 LU LU00100C patent/LUC00100I2/fr unknown
- 2019-03-01 HU HUS1900011C patent/HUS1900011I1/hu unknown
- 2019-03-07 LT LTPA2019007C patent/LTC1482932I2/lt unknown
- 2019-03-13 BE BE2019C510C patent/BE2019C510I2/fr unknown
- 2019-03-15 NL NL300974C patent/NL300974I2/nl unknown
- 2019-03-18 CY CY2019012C patent/CY2019012I2/el unknown

Also Published As

Publication number	Publication date
IL163995A0 (en)	2005-12-18
EP2275102A1 (fr)	2011-01-19
PL233493B1 (pl)	2019-10-31
TWI343377B (en)	2011-06-11
PL401636A1 (pl)	2013-05-27
US20100261717A1 (en)	2010-10-14
HK1141976A1 (en)	2010-11-26
SG2013013339A (en)	2014-12-30
US20100260714A1 (en)	2010-10-14
AU2003218157C1 (en)	2011-11-24
SI2130537T1 (sl)	2013-01-31
US20100267710A1 (en)	2010-10-21
PL230179B1 (pl)	2018-09-28
IL204420A (en)	2012-12-31
JP2008163034A (ja)	2008-07-17
BR122018007328B8 (pt)	2021-05-25
LTPA2019007I1 (lt)	2019-03-25
AR090144A2 (es)	2014-10-22
US20110158971A1 (en)	2011-06-30
DK2130537T3 (da)	2013-02-18
IL163995A (en)	2010-11-30
CN101633644A (zh)	2010-01-27
US8193229B2 (en)	2012-06-05
HUE025767T2 (en)	2016-05-30
JP5102642B2 (ja)	2012-12-19
TW201031641A (en)	2010-09-01
IS8959A (is)	2011-06-16
TWI338685B (en)	2011-03-11
IS2999B (is)	2018-06-15
EP2275102B1 (fr)	2015-07-29
IS8960A (is)	2011-06-16
CN101486682B (zh)	2013-08-14
SI1482932T1 (sl)	2010-02-26
PL377628A1 (pl)	2006-02-06
PL233177B1 (pl)	2019-09-30
HK1070823A1 (en)	2005-06-30
EP3000810A1 (fr)	2016-03-30
IL204419A (en)	2012-12-31
JP5498546B2 (ja)	2014-05-21
IS8961A (is)	2011-06-16
US8178693B2 (en)	2012-05-15
MXPA04008893A (es)	2005-06-20
NL300974I2 (nl)	2022-04-06
US20120277277A1 (en)	2012-11-01
NZ535158A (en)	2007-06-29
TW200407129A (en)	2004-05-16
ES2394347T3 (es)	2013-01-30
EP2130536B1 (fr)	2013-05-08
PL401637A1 (pl)	2013-05-27
DOP2003000613A (es)	2003-09-30
IS2998B (is)	2018-06-15
CN101633644B (zh)	2012-05-09
EP2130537B1 (fr)	2012-11-14
KR20040094786A (ko)	2004-11-10
US20030232869A1 (en)	2003-12-18
WO2003077914A1 (fr)	2003-09-25
TW201031642A (en)	2010-09-01
DK1482932T3 (da)	2010-02-01
CN101486682A (zh)	2009-07-22
US20080171778A1 (en)	2008-07-17
PL401638A1 (pl)	2013-05-27
AR038971A1 (es)	2005-02-02
IS7442A (is)	2004-09-09
CL2012002380A1 (es)	2012-11-05
JP2008019277A (ja)	2008-01-31
IL204419A0 (en)	2011-07-31
ATE449605T1 (de)	2009-12-15
HUS1900011I1 (hu)	2019-04-29
KR100984613B1 (ko)	2010-09-30
CA2478374A1 (fr)	2003-09-25
LUC00100I2 (fr)	2020-01-23
EP1482932B1 (fr)	2009-11-25
IS2990B (is)	2017-12-15
AU2009222613A1 (en)	2009-10-29
US20080177082A1 (en)	2008-07-24
SI2275102T1 (sl)	2015-12-31
EP1482932A1 (fr)	2004-12-08
US7576114B2 (en)	2009-08-18
EP2130536A1 (fr)	2009-12-09
RU2307831C2 (ru)	2007-10-10
EP1482932A4 (fr)	2006-04-05
ZA200407220B (en)	2007-05-30
JP4093966B2 (ja)	2008-06-04
PT3000810T (pt)	2017-10-25
CN100519539C (zh)	2009-07-29
US8193230B2 (en)	2012-06-05
AU2009222613B2 (en)	2011-06-16
SI3000810T1 (sl)	2017-10-30
RU2307831C9 (ru)	2008-06-10
KR100984573B1 (ko)	2010-09-30
PT2275102E (pt)	2015-10-27
CY1119136T1 (el)	2018-02-14
ES2407849T3 (es)	2013-06-14
DK2275102T3 (en)	2015-11-02
PA8569301A1 (es)	2004-10-08
EP2130537A1 (fr)	2009-12-09
US20050143438A1 (en)	2005-06-30
CN101633645A (zh)	2010-01-27
CN101633645B (zh)	2011-06-22
ES2549159T3 (es)	2015-10-23
CN1652776A (zh)	2005-08-10
AR090143A2 (es)	2014-10-22
PL401635A1 (pl)	2013-05-27
DOP2011000109A (es)	2011-11-30
LUC00100I1 (fr)	2019-02-13
AU2003218157B2 (en)	2009-07-09
TWI350285B (en)	2011-10-11
KR20100040760A (ko)	2010-04-20
CY2019012I1 (el)	2020-05-29
JP2005530709A (ja)	2005-10-13
CY2019012I2 (el)	2020-05-29
CY1109727T1 (el)	2014-09-10
ES2335276T3 (es)	2010-03-24
PT2130537E (pt)	2012-12-20
BR122018007328B1 (pt)	2020-03-03
US8003805B2 (en)	2011-08-23
UA77765C2 (en)	2007-01-15
CL2012002381A1 (es)	2012-11-05
US8513293B2 (en)	2013-08-20
JP2012224649A (ja)	2012-11-15
HK1153139A1 (zh)	2012-03-23
AU2003218157A1 (en)	2003-09-29
US8193231B2 (en)	2012-06-05
LTC1482932I2 (lt)	2020-04-27
US7425637B2 (en)	2008-09-16
SG148857A1 (en)	2009-01-29
CA2478374C (fr)	2009-01-06
US20100261718A1 (en)	2010-10-14
IL204420A0 (en)	2011-07-31
ES2635666T3 (es)	2017-10-04
DOP2013000023A (es)	2013-06-30
PT1482932E (pt)	2010-01-12
DOP2011000110A (es)	2011-11-30
EP3000810B1 (fr)	2017-07-19
US20100267793A1 (en)	2010-10-21
US7973170B2 (en)	2011-07-05
DK3000810T3 (en)	2017-10-16
SG194238A1 (en)	2013-11-29
KR20100040759A (ko)	2010-04-20
KR100984595B1 (ko)	2010-09-30
IS2748B (is)	2011-08-15
RU2004127926A (ru)	2005-06-27
US7777050B2 (en)	2010-08-17
DE60330227D1 (de)	2010-01-07

Publication	Publication Date	Title
BE2019C547I2 (fr)	2022-05-17
BE2019C510I2 (fr)	2022-05-19
BE2018C021I2 (fr)	2023-03-07
BE2017C049I2 (fr)	2022-08-09
BE2017C005I2 (fr)	2022-05-17
BE2016C069I2 (fr)	2022-05-17
BE2016C040I2 (fr)	2022-05-17
BE2016C013I2 (fr)	2022-05-17
BE2018C018I2 (fr)	2023-03-07
BE2016C002I2 (fr)	2023-03-07
BE2015C078I2 (fr)	2022-08-09
BE2015C017I2 (fr)	2022-09-22
BE2014C053I2 (fr)	2022-08-30
BE2014C051I2 (fr)	2022-08-09
BE2014C041I2 (fr)	2022-08-09
BE2014C016I2 (fr)	2023-03-07
BE2014C015I2 (fr)	2022-08-09
BRPI0302144A2 (fr)	2004-09-08
BRPI0215435A2 (fr)	2004-12-14
JP2002372700A5 (fr)	2005-11-04
JP2003234558A5 (fr)	2006-01-19
JP2003069343A5 (fr)	2009-10-08
JP2003138083A5 (fr)	2005-06-23
JP2003017532A5 (fr)	2005-07-14
JP2003181309A5 (fr)	2006-04-27